Showing 881-890 of 1017 results for "".
- FDA Limits Use of Nizoralhttps://practicaldermatology.com/news/20130730-fda_limits_use_of_nizoral/2459489/The FDA has limited the use of Nizoral (ketoconazole) oral tablets, warning that the oral tablets can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Gu
- SELF Magazine Awards Glytone “Best Night Cream”https://practicaldermatology.com/news/20130516-self_magazine_awards_glytone_best_night_cream/2459542/Glytone won one of SELF Magazine's 14th annual Healthy Beauty Awards, landing the distinction of “Best Night Cream” 2013 for Glytone Anti-aging Night Cream. The publication surveyed more than 1,600 US readers on their favorite beauty products—based on products that deliver on their promise—in five d
- Novan Therapeutics: Nitric Oxide May Inhibit Skin Steroidogenesis Locallyhttps://practicaldermatology.com/news/20130408-novan_therapeutics_nitric_oxide_may_inhibit_skin_steroidogenesis_locally/2459571/Novan Therapeutics reports topical nitric oxide-based therapies may reduce androgen levels in the skin by locally inhibiting skin steroidogenesis. The targeted reduction of androgens in the skin could lead to first-in-class local antiandrogen products to treat acne and androgenic alopecia (male patt
- Cynthia Nixon Partners with Galderma and the NRS to Raise Awareness for Rosaceahttps://practicaldermatology.com/news/20130314-cynthia_nixon_partners_with_galderma_and_the_nrs_to_raise_awareness_for_rosacea/2459591/Actress Cynthia Nixon recently joined with dermatologists Rick Fried, MD and Flor Mayoral, MD and a panel of other experts at the "Face to Face with Rosacea: Empowering Professionals and Patients" educational event at the AAD Meeting in Miami. Sponsored by Galderma in conjunction with the National R
- Nickel Reactions on the Rise. Diet to Blame?https://practicaldermatology.com/news/20120302-nickel_reactions_on_the_rise_diet_to_blame/2459857/Certain patients consuming healthy diets consisting of whole grains, legumes, nuts, and soy may be at increased risk of developing allergic reactions to nickel, according to dermatologist Matthew Zirwas, MD, an associate professor at
- Dr. Raj Chovatiya: Lebrikizumab Long-Term Data Makes 'Night and Day' Differencehttps://practicaldermatology.com/news/Dr-Raj-Chovatiya-Lebrikizumab-Long-Term-Data-Makes-Night-Day-Difference/2471865/New long-term results presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showed complete skin clearance (EASI-100 or IGA 0) at 3 years in patients with moderate-to-severe atopic dermatitis taking lebrikizumab (EBGLYSS™, Eli Lilly and Company) in the AD
- Upadacitinib Improves Night-time Itch and Sleep Disturbance: Studyhttps://practicaldermatology.com/news/analysis-upadacitinib-improves-night-time-itch-and-sleep-disturbance/2462217/Researchers publishing the poster at Maui Derm 2024 analyzed integrated data from the Measure Up 1 and Measure Up 2 phase-3 randomized, double-blinded studies looking the safety and efficacy of upadacitinib 15 mg (UPA 1
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technolog
- Vial, Nielsen BioSciences Partner in Phase III Clinical Trial of Candin for Common Wartshttps://practicaldermatology.com/news/vial-nielsen-biosciences-partner-in-phase-iii-clinical-trial-of-candin-for-common-warts/2461783/Vial is partnering with
- CHMP Recommends European Approval of Nivolumab/Relatimab for Certain Melanomashttps://practicaldermatology.com/news/chmp-recommends-european-approval-of-nivolumabrelatimab-for-certain-melanomas/2461278/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of